Work

Abstract C216: Phase 1, first-in-human, dose-escalation study of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies

Year: 2009

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-09-c216

Authors: Razelle Kurzrock, Jennifer Wheler, David S. Hong, Zhong Guo, Mary F. Mulcahy, Al B. Benson, Sanjay Goel, Umang Swami, Sridhar Mani, Aby Buchbinder

Institutions: The University of Texas MD Anderson Cancer Center, Northwestern University, Albert Einstein College of Medicine, Montefiore Einstein Comprehensive Cancer Center, Enzon Pharmaceuticals (United States)

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1982300692

Cites:

Cited by: 6

Related to: 10